1. Semglee, Insulin Glargine co-developed by Biocon and Mylan, is the first biosimilar from the partnered portfolio to be approved in the developed markets of EU and Australia. 2. Biocon also received Insulin Glargine approval in South Korea and biosimilar Trastuzumab approval in Turkey. 3. Biocon and Mylan agreed to accelerate the introduction of biosimilar Adalimumab in Europe through Mylan's in-licensing arrangement with Fujifilm Kyowa Kirin Biologics, to enable launch in EU, around market formation. 4. Biocon and Mylan have agreed to expand their long-standing collaboration to add two new next-generation biosimilar programs with Insulin Glargine 300 units/mL and Pertuzumab.